期刊文献+

aPKC-ι在非小细胞肺癌组织中的表达及其与预后的关系 被引量:1

下载PDF
导出
摘要 目的研究非典型蛋白激酶C-ι(aPKC-ι)在非小细胞肺癌(NSCLC)组织中的表达,探讨其表达与NSCLC各临床病理因素及其预后的关系。方法采用免疫组织化学染色法检测80例NSCLC癌组织和20例肺良性疾病组织中aPKC-ι蛋白的表达情况,并随访所有患者的生存时间。结果NSCLC组织中aPKC-ι蛋白表达较肺良性疾病组织明显增高(P=0.006),aPKC-ι表达与性别(P=0.806)、组织学类型(P=0.140)差异无统计学意义,与淋巴结转移(P=0.003)、病理分期(P=0.000)、分化程度(P=0.006)差异有统计学意义;生存分析显示:aPKC-ι表达与预后明显相关(r=0.914)。结论aPKC-ι的表达强弱与NSCLC的发生及发展有关,可作为NSCLC患者预后参考指标,有利于个体化治疗。
出处 《中国胸心血管外科临床杂志》 CAS 2010年第1期81-83,共3页 Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
  • 相关文献

参考文献10

  • 1Gazclar AF, Lam S, Wistuba II. Molecular and cytologic techniques of early detection. In: Lung Cancer: principles and practice. Pass HI, eds. 2nd eel. Philadelphia: Lippincott Williams & Wilkins, 2000. 4072-4424.
  • 2Zhang L, H uang J, Yang N, et a l. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res,2006,66(9) :4627-4635.
  • 3Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res, 2006,12(18) :5336-5345.
  • 4Regala RP, Weems C, Jamieson L,et al. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem, 2005, 280(35):31109-31115.
  • 5Suzuki A, Akimoto K, Ohno S. Protein kinase C lambda/iota ( PKC lambda/iota ) : a PKC isotype essential for the development of multicellular organisms. J Biochem, 2003, 133 (1) :9-16.
  • 6Eder AM, Sui X, Rosen DG, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA, 2005,102(35):12519-12524.
  • 7Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res, 2005,65(19) :8905-8911.
  • 8Eder AM, Sui X, Rosen DG, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A, 2005,102(35) :12519-12524.
  • 9Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase Ciota is an oncogene in human non-small cell lung cancer. Cancer Res, 2005,65 ( 19 ) : 8905-8911.
  • 10Fields AP, Frederick LA, Regala RP. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Bioehem Soc Trans, 2007,35(Pt 5):996-1000.

同被引文献37

  • 1刘世英,蒋宇扬,曹健,刘峰,马丽,赵玉芬.蛋白激酶C的抑制剂[J].科学通报,2005,50(5):405-415. 被引量:9
  • 2Mellor H, Parker PJ. The extended protein kinase C superfamily [J] . Biochem J, 1998, 332 (Pt2) : 281-292.
  • 3Gschwendt M. Protein kinase C delta [J] . Eur J Biochem, 1999, 259 (3) : 555-564.
  • 4Nishizuka Y. Protein Kinase C and lipid signaling for sustained cellular responses [J] . FASEB J, 1995, 9 (7) : 484-496.
  • 5Ashhar S Ali, Shadan Ali, Bassel F E1-Rayes, et ol. Exploitation of protein kinase C: a useful target for cancer therapy [J] . Cancer Treat Rev, 2009, 35 (1) : 1-8.
  • 6Mackay H J, Twelves CJ. Targeting the protein kinase C family: are we there yet? [J] . Nat Rev Cancer, 2007, 7 (7) : 554-562.
  • 7Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target [J] . PharmacolRes, 2007, 55 (6) : 487-497.
  • 8Huber TB, Hartleben B, Winkelmann K, et al. Loss of podoeyte aPKC dA causes polarity defects and nephrotic syndrome [J] . J Am Soc Nephrol, 2009, 20 (4) : 798-806.
  • 9Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses [J] . FASEB J, 1995, 9 (7) : 484-496.
  • 10Da Rocha AB, Mans DR, Regner A, et al. Targeting protein kinase C: new therapeutic opportunities against high grade malignant gliomas [J] . Oncologist, 2002, 7 (1) : 17-33.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部